RxDoctor Payments Data

Megan Barnwell, MD

Cardiovascular Disease · San Antonio, TXNPI 1629238092

Payments from drug & device makers

$2,458in general payments, 2019–2025

Across 147 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$718
  • Johnson & Johnson$430
  • Amgen$323
  • Lexicon Pharmaceuticals, Inc.$163
  • Esperion Therapeutics, Inc.$98
  • Amarin Pharma, Inc.$94
  • plus $634 from 14 others

What the payments were for

  • Food & beverage$2,458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,458 in reported general payments places this provider in the 35th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$178,524
Medicare patients
317
Services billed
2,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban206$204,949
XareltoRivaroxaban112$133,147
Repatha SureclickEvolocumab42$44,443
EntrestoSacubitril/Valsartan37$33,906
JardianceEmpagliflozin20$20,040
EdarbiAzilsartan Medoxomil15$13,032
Nebivolol Hcl99$7,683
Diltiazem 12hr ErDiltiazem Hcl12$3,249
Rosuvastatin Calcium286$2,912
EdarbyclorAzilsartan Med/Chlorthalidone12$2,776
Atorvastatin Calcium231$2,338
Carvedilol284$2,238
Valsartan52$2,099
Metoprolol Succinate124$1,859
Olmesartan Medoxomil109$1,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$36$204,949206 claims
Johnson & JohnsonXarelto$430$133,147112 claims
NovartisEntresto$718$33,90637 claims
Boehringer IngelheimJardiance$94$20,04020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →